for MFHWs, when considering the stress sensitivity effect, can be obtained as
According to the company, TRUMENBA is a sterile suspension composed of two recombinant lipidated factor H binding protein (fHBP
) variants from N.
Using 15% IgG-depleted human serum as a complement source, we found the strain was susceptible (titer >40) to bactericidal activity of mouse antiserum to recombinant FHbp ID 1, the subfamily B subvariant in the MenB-4C vaccine but not to mouse antiserum to NadA (not expressed by the strain) or to FHbp ID 22 (a subfamily A subvariant not in the vaccine) (titers <10).
A postmortem serum sample had high IgG reactivity against FHbp and NHba, both expressed by the infecting strain, and low reactivity to NadA (Figure 1).
([dagger]) hSBA titer [greater than or equal to] 1:16 for the serogroup B strain expressing FHbp
(factor H binding protein) A22.
PorA, PorB, and FetA were classified according to their respective variable regions, NadA was categorized by the Novartis convention of variant and peptide identifier (24), NhbA was identified by PubMLST peptide identifier, and FHbp was identified by the PubMLST peptide identifier and the Pfizer peptide identifier (subfamilies A and B).
The NmC ST-10127 isolates contained FHbp peptide 27, belonging to subfamily A and with 5 aa substitutions relative to peptide 19, against which Trumenba is likely effective on the basis of serum bactericidal activity using human complement (hSBA) (18).
Recently, we reported the predominance of noncross-protective PorA (P1.5,2) and fHbp
variants (variant 2 peptide 22) among endemic MenW:cc11 isolates (3).
The fHbp genetic variant was identified as described by Brehony et al.
In addition, sequence analysis of the fHbp gene identified allele 22 as the most common variant; it was present in 58 (96.7%) of 60 strains that belonged to the W serogroup (Table 2).
Multilocus sequence typing and genotypic analysis of PorA variable regions (VRs) (porA VR1 and VR2), ferric enterochelin receptor VR (fetA), neisserial heparin-binding antigen (nhba), neisserial adhesin A (nadA), and factor H binding protein (fhbp
) encoding regions were performed by using described protocols (11,12).
Molecular testing on the outbreak strain detected the gene coding for FHbp
B24 (6), predicting cross-protection with both MenB vaccines (7).